lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-κB Signaling Pathway
Cancer Biotherapy and Radiopharmaceuticals · 01.03.2021 · 36 (2) · 202-210
DOI: 10.1089/cbr.2019.3363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, erschienen am 01.03.2021. Verfasst von Yuzi Zhao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan City, China. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynaecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan City, China.
Zitieren
APA
Zhao, Y., & Hong, L. (2021). lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-κB Signaling Pathway. Cancer Biotherapy and Radiopharmaceuticals, 36(2), 202-210. https://doi.org/10.1089/cbr.2019.3363
Vancouver
Zhao Y, Hong L. lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-κB Signaling Pathway. Cancer Biotherapy and Radiopharmaceuticals. 2021;36(2):202-210. doi:10.1089/cbr.2019.3363
BibTeX
@article{Zhao2021,
author = {Zhao, Yuzi and Hong, Li},
title = {lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-κB Signaling Pathway},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2021},
volume = {36},
number = {2},
pages = {202--210},
doi = {10.1089/cbr.2019.3363}
}
EUVIMED